OPKO Health Overview
- Year Founded
-
1991

- Status
-
Public
- Employees
-
3,930

- Stock Symbol
-
OPK

- Investments
-
44
- Share Price
-
$1.61
- (As of Wednesday Closing)
OPKO Health General Information
Description
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a world supply-chain operation and holding company in Ireland. It also owns a specialty active pharmaceutical ingredients manufacturer in Israel. It operates in two segments Diagnostics and Pharmaceuticals.
Contact Information
Corporate Office
- 4400 Biscayne Boulevard
- Miami, FL 33137
- United States
Corporate Office
- 4400 Biscayne Boulevard
- Miami, FL 33137
- United States
OPKO Health Timeline
OPKO Health Stock Performance
As of 05-Feb-2025, OPKO Health’s stock price is $1.61. Its current market cap is $1.08B with 673M shares.
(As of Wednesday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$1.61 | $1.56 | $0.86 - $1.76 | $1.08B | 673M | 4M | -$0.19 |
OPKO Health Financials Summary
As of 30-Sep-2024, OPKO Health has a trailing 12-month revenue of $711M.
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
---|---|---|---|---|
EV | 1,259,933 | 1,336,516 | 1,077,248 | 3,372,950 |
Revenue | 711,408 | 863,495 | 1,004,196 | 1,774,718 |
EBITDA | 13,919 | (69,499) | (272,791) | 83,543 |
Net Income | (133,734) | (188,863) | (328,405) | (30,143) |
Total Assets | 2,256,103 | 2,011,698 | 2,167,259 | 2,399,715 |
Total Debt | 512,316 | 326,564 | 305,548 | 254,755 |
OPKO Health Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
OPKO Health Comparisons
Industry
Financing
Details
OPKO Health Competitors (52)
One of OPKO Health’s 52 competitors is Novartis, a Corporation company based in Basel, Switzerland.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Novartis | Corporation | Basel, Switzerland | ||||
EMD Serono | Corporation | Boston, MA | ||||
Intas Pharmaceuticals | Private Equity-Backed | Ahmedabad, India | ||||
Roche | Corporation | Basel, Switzerland | ||||
GSK | Corporation | Middlesex, United Kingdom |
OPKO Health Patents
OPKO Health Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
CA-2991898-A1 | Heteroaryl carbonitriles for the treatment of disease | Inactive | 15-Jul-2015 | ||
US-20180153872-A1 | Heteroaryl carbonitriles for the treatment of disease | Inactive | 15-Jul-2015 | ||
EP-3322422-A1 | Heteroaryl carbonitriles for the treatment of disease | Inactive | 15-Jul-2015 | ||
US-20240148694-A1 | Treatment of androgen deprivation therapy associated symptoms | Pending | 11-Sep-2014 | ||
CA-2814951-A1 | Hypersulfated disaccharides to treat elastase related disorders | Inactive | 29-Oct-2010 | A61K31/7016 |
OPKO Health Signals
OPKO Health Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
OPKO Health Investments & Acquisitions (44)
OPKO Health’s most recent deal was a Merger/Acquisition with ModeX Therapeutics for . The deal was made on 09-May-2022.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
ModeX Therapeutics | 09-May-2022 | Merger/Acquisition | Biotechnology | ||
HealthSnap | 01-Nov-2021 | Later Stage VC | Outcome Management (Healthcare) | ||
Joint Venutre (LeaderMed Health Group / OPKO Health) | 14-Sep-2021 | Joint Venture | Drug Discovery | ||
Eloxx Pharmaceuticals | 02-Aug-2017 | Later Stage VC | Biotechnology | ||
VBI Vaccines | 06-Dec-2016 | PIPE | Drug Discovery |
OPKO Health ESG
Risk Overview
Risk Rating
Updated July, 13, 2024
32.4 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,120
Rank
Percentile

Pharmaceuticals
Industry
of 853
Rank
Percentile

Biotechnology
Subindustry
of 368
Rank
Percentile

OPKO Health Exits (12)
OPKO Health’s most recent exit was on 02-Aug-2017 from Eloxx Pharmaceuticals. The exit was categorized as with 12 buyers.
Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
---|---|---|---|---|---|
Eloxx Pharmaceuticals | 02-Aug-2017 | Completed |
|
||
VBI Vaccines | 06-Dec-2016 | Completed |
|
||
Arno Therapeutics | 16-Aug-2016 | Completed |
|
||
VBI Vaccines | 21-Jun-2016 | Completed |
|
||
Sevion Therapeutics | 01-Aug-2015 | PIPE | Completed |
|
Affiliates
Subsidiaries (3)
Name | Industry | Location | Year Founded |
---|---|---|---|
EirGen Pharma | Waterford, Ireland | 2006 | |
OPKO Biologics | Kiryat Gat, Israel | 2001 | |
BioReference Health | Elmwood Park, NJ | 1981 |
OPKO Health FAQs
-
When was OPKO Health founded?
OPKO Health was founded in 1991.
-
Where is OPKO Health headquartered?
OPKO Health is headquartered in Miami, FL.
-
What is the size of OPKO Health?
OPKO Health has 3,930 total employees.
-
What industry is OPKO Health in?
OPKO Health’s primary industry is Drug Discovery.
-
Is OPKO Health a private or public company?
OPKO Health is a Public company.
-
What is OPKO Health’s stock symbol?
The ticker symbol for OPKO Health is OPK.
-
What is the current stock price of OPKO Health?
As of 05-Feb-2025 the stock price of OPKO Health is $1.61.
-
What is the current market cap of OPKO Health?
The current market capitalization of OPKO Health is $1.08B.
-
What is OPKO Health’s current revenue?
The trailing twelve month revenue for OPKO Health is $711M.
-
Who are OPKO Health’s competitors?
Novartis, EMD Serono, Intas Pharmaceuticals, Roche, and GSK are some of the 52 competitors of OPKO Health.
-
What is OPKO Health’s annual earnings per share (EPS)?
OPKO Health’s EPS for 12 months was -$0.19.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »